Forum Topics CCA CCA Thesis

Pinned straw:

Last edited a month ago

CCA has long promised growth and profitability. Well, that promise is finally coming true, yet the market hasn't noticed.

Transactional revenue for the payments platform went from 1.3m in FY24 to 6.3m (USD) in FY25. This is platform revenue and was driven by an increase in active cards in New Zealand. They clip the ticket on these card transactions with a flat fee per transaction as well as the interchange fee. By cards, that's physical and digital cards (higher fee).

My thesis is that over the long term this platform transactional revenue will continue to grow and margins will improve.

The business is not yet high-margin - gross margins are around 27% - and card issuing is a competitive, mature market. However, if CCA retains clients on its platform and scales, margins could rise significantly (the company targets 50% gross margin).

Development for their core products is largely complete, meaning ongoing development costs should remain relatively stable. Revenue quality is solid: 76% of FY25 revenue came from recurring platform-as-a-service (Vertexon) and support/maintenance services. The remainder came from Paysim, a payment testing product.

One negative is the poor working capital setup. In September 2024, on-boarding several new customers required a ~$1 m capital raise to bridge the 6-8 week gap between payments and receipts. They now have a higher revenue base, and more reoccurring revenue, so this timing effect should be reduced in future.

Another negative is their small size, the revenue lumpiness and that any customer loss will be felt. Perhaps they will continue to remain sub-scale and never fulfill the promise.

As written up well by @Wini in July 2024 there's the potential for operating leverage. While FY25 NPAT was still negative, they had positive operating cashflow and positive EBITDA for the first time. The operating leverage is starting to show through.

In late 2024, the company decided to exit the U.S. market and focus on Australia. Management is now concentrating on two core products, enhancing them using the existing development infrastructure rather than launching new products. This is a sensible, mature decision, though the market may penalize the company for lacking long-term growth ambitions. I like a tightly run, simpler business focusing on a much easier (even if smaller) market.

Recently Q1 FY26 results showed quarterly growth of 22% in active cards on the platform and record quarterly revenue of A$7.1m (partly from one-off hit of new license sales). The FY26 guidance of A$25.4-27.7m, Underlying EBITDA A$3.8-5.4m and cash flow positivity is eminently achievable considering these Q1 results, contract liabilities already on balance sheet and cost out from the US pivot. This is without significant scale and shows the quality of the business.

Management has been very transparent and detailed in their recent communications, so much so that I find myself questioning why this opportunity exists and whether I might be missing something.

With a market cap of ~50m (similar to July 2024) the market has not rewarded the sensible strategic decision making of management and it's execution. I think it is decent value, taking the upper end of FY26 guidance, I've got it on less than 2x revenue and EV/EBITDA of 9x. 

The other aspect of why this opportunity exists may be the long road it has been for investors with Change Financial. The market cap has not grown much over the years, it hasn't delivered on the promise. Well, I think there's some evidence that has changed and I'm a recent owner

Wini
Added a month ago

Well written @twee.

"I find myself questioning why this opportunity exists and whether I might be missing something". This is one of the most important questions we have to ask as investors, but I've also come to learn that in microcaps that have been beaten down for an extended period of time to never underestimate the time a share price will churn even as the underlying fundamentals turnaround.

I agree there is plenty of operating leverage to come through for CCA. As you point out, the PaaS segment is still sub-scale, generating 27% GM's in FY25, but there was a significant split between the halves there with 1H coming in at 19% while the 2H improved substantially to 32%. Management called out a few factors for this, but primarily they were still scaling revenue over the fixed cost base (largely Mastercard network fees) and compliance/certification for Apple/Google Pay roll-outs.

I expect margins to trend towards management's 50% target pretty quickly. The fintech customers being onboarded will be higher margin than the current credit union debit card customers, plus their pre-paid programs come with a float that CCA can generate 100% margin interest income on. It was only $2.8m at the end of FY25 but it should grow nicely over time and be another tidy income stream.

I've also become more bullish on the activity of these fintech customers. Extraordinary was CCA's first fintech customer, and their product was originally corporate pre-paid cards used for employee gifting and wellness. An interesting product, but one that might only be tapped a handful of times a year by end users. However they recently obtained approval from NZ Inland Revenue for their cards to be FBT exempt for public transport to work which has rapidly expanded their customer base but also means the cards can turn into a daily tap.

Sharesies is another good win, but despite the large customer base I was unsure what the take up would look like for their card program. But they have come out recently and said spending on their cards will generate a 1% cashback that will go back into their customers investment accounts. Still hard to know exactly what the take up will be, but with that benefit I think we see a good chunk of users turn it into their daily use debit card.

Looking forward to the next CCA update in January, the 1Q was stronger than I expected (mostly driven by the one-off licence sales as you noted) and given the 2Q seasonality I'm hoping for another good result.

30